1789 Stock Overview
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, Taiwan, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
ScinoPharm Taiwan, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$28.00 |
| 52 Week High | NT$35.80 |
| 52 Week Low | NT$24.30 |
| Beta | 0.30 |
| 1 Month Change | 5.66% |
| 3 Month Change | 10.02% |
| 1 Year Change | 3.13% |
| 3 Year Change | -4.44% |
| 5 Year Change | 10.45% |
| Change since IPO | -36.43% |
Recent News & Updates
Recent updates
Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First
Apr 04
A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Mar 14Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock
Feb 21ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares
Jan 25
We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease
Jan 04Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Dec 14Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?
Nov 23Shareholder Returns
| 1789 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 3.9% | -8.2% | -5.7% |
| 1Y | 3.1% | 3.8% | 23.8% |
Return vs Industry: 1789 matched the TW Pharmaceuticals industry which returned 3.8% over the past year.
Return vs Market: 1789 underperformed the TW Market which returned 23.8% over the past year.
Price Volatility
| 1789 volatility | |
|---|---|
| 1789 Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.5% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1789 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1789's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Susan Lu | www.scinopharm.com |
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, Taiwan, and internationally. The company offers small molecular drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates.
ScinoPharm Taiwan, Ltd. Fundamentals Summary
| 1789 fundamental statistics | |
|---|---|
| Market cap | NT$21.71b |
| Earnings (TTM) | NT$287.06m |
| Revenue (TTM) | NT$3.19b |
77.1x
P/E Ratio6.9x
P/S RatioIs 1789 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1789 income statement (TTM) | |
|---|---|
| Revenue | NT$3.19b |
| Cost of Revenue | NT$1.97b |
| Gross Profit | NT$1.22b |
| Other Expenses | NT$928.93m |
| Earnings | NT$287.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.36 |
| Gross Margin | 38.17% |
| Net Profit Margin | 9.01% |
| Debt/Equity Ratio | 0.3% |
How did 1789 perform over the long term?
See historical performance and comparison